Fisetin to Reduce Senescence and Mobility Impairment in PAD (NCT06399809)
Fisetin to Reduce Senescence and Mobility Impairment in Peripheral Artery Disease: the FIRST Pilot Randomized Trial
🩺 Plain-English Summary (8th-Grade Level)
The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD). the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in people with peripheral artery disease. In exploratory analyses, the investigators will assess whether Fisetin reduces interleukin-6 (IL-6) and novel senescent markers in adipose tissue, muscle, and/or blood.
Who can join: Review the eligibility criteria below.
Location: Northwestern University Feinberg School of Medicine — Chicago, Illinois
Age range: 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Northwestern University Feinberg School of Medicine — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (312) 503-6419
Email: mdm608@northwestern.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Peripheral Arterial Disease
- SELUTION4SFA Trial — Little Rock, Arkansas
- SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs — New Haven, Connecticut
- A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND) — Birmingham, Alabama
- Shortwave Diathermy In-home Treatment for Indianapolis VA-only Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy — Indianapolis, Indiana
- FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease — Chicago, Illinois
- MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology — Omaha, Nebraska
Explore by condition: All Peripheral Arterial Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.